Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases
April 29, 2024 06:53 ET
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...
Global DNA Repair Drugs Market Poised for Remarkable Growth: Key Insights and Projections for 2024-2034
January 30, 2024 03:33 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global DNA Repair Drugs Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. Emerging Trends and...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
January 11, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
October 19, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
October 07, 2022 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...
Global Human Recombinant DNA Market Analysis Report 2022-2027 Featuring Abbvie, Alexion Pharmaceuticals, Amgen, Eli Lilly, Merck & Co, Sanofi, & Takeda Pharmaceutical
August 04, 2022 06:43 ET
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Human Recombinant DNA: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report highlights the current and future market...
DNA Damage Response (DDR) Drugs in Oncology Analytical Tool 2022: The Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
July 26, 2022 04:43 ET
|
Research and Markets
Dublin, July 26, 2022 (GLOBE NEWSWIRE) -- The "DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. DNA Damage Response (DDR)...
InvestmentPitch Media Video Discusses Rakovina Therapeutics and its Presentation of Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research Annual General Meeting
April 14, 2022 06:00 ET
|
InvestmentPitch Media and Rakovina Therapeutics
VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel...
NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April
March 30, 2022 07:00 ET
|
NERx Biosciences
INDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology company led by John Turchi and Katherine Pawelczak, will be presenting on two pre-clinical pipeline drugs that may have...
Worldwide DNA Repair Drugs Industry to 2026 - by Technology Type, Application and Region
February 25, 2022 09:23 ET
|
Research and Markets
Dublin, Feb. 25, 2022 (GLOBE NEWSWIRE) -- The "DNA Repair Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth examination of the...